US 8,940,945 B2 · Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases

Abstract

The subject invention provides a myricanol compound that is in predominant form of (+)-αR,11S-myricanol as compared to (−)-αS,11R-myricanol. In one embodiment, the (+)-αR,11S-myricanol is isolated from Myrica cerifera, and is in about 86% enantiomeric excess of (−)-αS,11R-myricanol. The subject invention also pertains to therapeutic compositions and methods for treatment of neurodegenerative diseases, in particular, neurodegenerative diseases associated with abnormal accumulation of protein tau. Specifically exemplified herein is the therapeutic use of myricanol and myricanone isolated from root barks of Myrica species. Also provided are methods for preparing extracts of the subject invention from Myrica species.

Claims3

Dependent claims

A method of preparing a Myrica extract comprising myricanol, comprising:

a) providing a sufficient quantity of raw material of a Myrica species;
b) extracting the raw material with toluene to yield a toluene fraction and a first residue;
c) mixing the first residue with ethanol to yield an ethanol fraction and a second residue;
d) mixing the second residue with CMT buffer comprising about 30% chloroform, 10% methanol and 0.002% trifluoroacetic acid (TFA) to obtained a CMT extract;
and
e) fractionating the CMT extract using MPLC and recovering the fraction that comprises myricanol.

3 more elements

Dependencies are inferred from the claim text.

Facts

Application

13/810,362Filed 25 Jul 2011 · us provisional application

Priority

23 Jul 2010

Published

US 2013/0184353 A118 Jul 2013

Granted

27 Jan 2015

Term ends

Not estimatedThe source records don’t support an estimate.

Classification12 codes

C07C 43/23
Having an ether-oxygen atom bound to a carbon atom of a six-membered aromatic ring: containing hydroxy or O-metal groups
A61K 31/09
Having an ether linkage to aromatic ring nuclear carbon: having two or more such linkages
A61K 36/185
Magnoliophyta: magnoliopsida
A61P 25/28
Drugs for disorders of the nervous system: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents,…

Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases

Life of this patent

Materials and methods for reduction of protein tau and treatment of neurodegenerative diseases

Life of this patent

Abstract

Claims3